TELAPREVIR- BASED THERAPY IN G1 HCV-INFECTED PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN: REALIZE TRIAL FINAL RESULTS

被引：0
|
作者：
Foster, G. [1 ]
Zeuzem, S. [2 ]
Andreone, P. [3 ]
Pol, S. [4 ,5 ]
Lawitz, E. [6 ]
Diago, M. [7 ]
Roberts, S. [8 ]
Focaccia, R. [9 ]
Younossi, Z. [10 ]
H, A. [11 ]
Heeswijk, R. V. [12 ]
de Meyer, S. [12 ]
Luo, D. [13 ]
Picchio, G. [13 ]
Beumont, M. [12 ]
机构：
[1] Queen Mary Univ London, Inst Cell & Mol Sci, London, England
[2] Goethe Univ Frankfurt, Med Ctr, D-60054 Frankfurt, Germany
[3] Univ Bologna, Bologna, Italy
[4] Univ Paris 05, INSERM, U567, Paris, France
[5] Hop Cochin, AP HP, F-75674 Paris, France
[6] Alamo Med Res, San Antonio, TX USA
[7] Hosp Gen Valencia, Valencia, Spain
[8] Alfred Hosp, Dept Gastroenterol, Melbourne, Vic, Australia
[9] Emilio Ribas Infect Dis Inst, Sao Paulo, Brazil
[10] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA
[11] Med Univ Warsaw, Warsaw, Poland
[12] Tibotec BVBA, Beerse, Belgium
[13] Tibotec Inc, Titusville, NJ USA
来源：
GUT | 2011年 / 60卷
关键词：
D O I：
10.1136/gutjnl-2011-300857b.3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP03
引用
收藏
页码：A50 / A51
页数：6
相关论文
共 50 条
  • [41] Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies
    Wedemeyer, Heiner
    Forns, Xavier
    Hezode, Christophe
    Lee, Samuel S.
    Scalori, Astrid
    Voulgari, Athina
    Le Pogam, Sophie
    Najera, Isabel
    Thommes, James A.
    PLOS ONE, 2016, 11 (01):
  • [42] VIROLOGICAL RESPONSE AND TOLERANCE TO BOCEPREVIR OR TELAPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN TRIPLE THERAPY IN HIV-HCV CO-INFECTED PATIENTS: REAL-LIFE FINDINGS FROM THE PAN STUDY
    Baumgarten, A.
    Holm, S.
    Lutz, T.
    Schranz, D.
    Mauss, S.
    Hillenbrand, H.
    Moll, A.
    Scholten, S.
    Schmidt, W.
    Goelz, J.
    Hintsche, B.
    Schleehauf, D.
    Fenske, S.
    Stephan, C.
    Prziwara, D.
    Koeppe, S.
    Alshuth, U.
    Jaeger, H.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S464 - S464
  • [43] HIGH SVR24 RATES WITH MERICITABINE (MCB), TELAPREVIR (TVR) PLUS PEGIFN ALFA-2a/RIBAVIRIN (P/R) IN HCV G1-INFECTED PRIOR NULL RESPONDERS: RESULTS FROM DYNAMO 2
    Sherman, K. E.
    Forns, X.
    Scalori, A.
    Zhao, S.
    Voulgari, A.
    Thommes, J.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S502 - S502
  • [44] Mutation frequency of NS5A in patients vertically infected with HCV genotype 1 predicts sustained virological response to peginterferon alfa-2b and ribavirin combination therapy
    Jenke, A. C. W.
    Moser, S.
    Orth, V.
    Zilbauer, M.
    Gerner, P.
    Wirth, S.
    JOURNAL OF VIRAL HEPATITIS, 2009, 16 (12) : 853 - 859
  • [45] Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program
    Bruno, S.
    Bollani, S.
    Zignego, A. L.
    Pascasio, J. M.
    Magni, C.
    Ciancio, A.
    Caremani, M.
    Mangia, A.
    Marenco, S.
    Piovesan, S.
    Chemello, L.
    Babudieri, S.
    Moretti, A.
    Gea, F.
    Colletta, C.
    Perez-Alvarez, R.
    Forns, X.
    Larrubia, J. R.
    Arenas, J.
    Crespo, J.
    Calvaruso, V.
    Silberstein, F. Ceccherini
    Maisonneuve, P.
    Craxi, A.
    Calleja, J. L.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (05) : 469 - 480
  • [46] CLINICAL UTILITY OF THE REALTIME HCV ASSAY (ABBOTT MOLECULAR) FOR RESPONSE-GUIDED THERAPY IN PATIENTS INFECTED WITH HCV GENOTYPES 1, 2, OR 3 AND TREATED WITH PEGINTERFERON-ALFA PLUS RIBAVIRIN (PEGIFN/RBV)
    Vermehren, Johannes
    Yu, Ming-Lung
    Monto, Alexander
    Yao, Joseph D.
    Anderson, Christopher
    Bertuzis, Rasa
    Schneider, George
    Sarrazin, Christoph
    HEPATOLOGY, 2010, 52 (04) : 789A - 790A
  • [47] RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS INFECTED WITH HCV GENOTYPE 1: INTERIM RESULTS FROM THE TriCo STUDY
    Ferenci, P.
    Flisiak, R.
    Caruntu, F. A.
    Lengyel, G.
    Hohmann, M.
    Bakalos, G.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S453 - S454
  • [48] PREDICT STUDY FINAL RESULTS: EFFICACY AND SAFETY OF 24-WK REGIMEN OF PEGINTERFERON ALFA-2B PLUS WEIGHT-BASED RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 (G1) WITH LOW VIRAL LOAD WHO ACHIEVE RAPID VIRAL RESPONSE
    Craxi, Antonio
    Zuckerman, Eli.
    Koutsounas, Sotirios
    Ogurtsov, Pavel P.
    Chemello, Liliana
    Maticic, Mojca B.
    Torras, Xavier
    Diago, Moises
    Tartaglione, Mariateresa
    Witthoeft, Thomas
    Yu, Xin
    Chaudhri, Eirum I.
    Pedicone, Lisa
    Faruqi, Rab
    HEPATOLOGY, 2009, 50 (04) : 693A - 694A
  • [49] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin (Copegus®) in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin:: Final results of the Spanish High-Dose Induction Pilot Trial.
    Diago, M
    Romero-Gomez, M
    Crespo, J
    Olveira, A
    Perez, R
    Barcena, R
    Sanchez-Tapias, JM
    Munoz-Sanchez, M
    HEPATOLOGY, 2004, 40 (04) : 389A - 389A
  • [50] HIGH SUSTAINED VIROLOGICAL RESPONSE RATES WITH RESPONSE-GUIDED DANOPREVIR PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE, HCV GENOTYPE 1 PATIENTS: ATLAS STUDY FINAL RESULTS
    Marcellin, P.
    Cooper, C.
    Balart, L. A.
    Larrey, D. G.
    Box, T. D.
    Yoshida, E.
    Lawitz, E.
    Buggisch, P.
    Ferenci, P.
    Weltman, M.
    Labriola-Tompkins, E.
    Le Pogam, S.
    Najera, I.
    Thomas, D. N.
    Hooper, G.
    Shulman, N.
    Zhang, Y.
    Navarro, M. T.
    Lim, C. Y.
    Brunda, M.
    Yetzer, E. S.
    Terrault, N.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S472 - S472
12345